XOMA Earns $5M Milestone Upon FDA Acceptance Of Day One's Tovorafenib NDA For Relapsed Or Progressive Pediatric Low-Grade Glioma (pLGG)
Portfolio Pulse from Benzinga Newsdesk
XOMA Corporation has earned a $5 million milestone payment following the FDA's acceptance of Day One Biopharmaceuticals' New Drug Application (NDA) for Tovorafenib, a treatment for relapsed or progressive pediatric low-grade glioma (pLGG).
October 31, 2023 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
XOMA's receipt of a $5 million milestone payment following the FDA's acceptance of Day One's NDA for Tovorafenib could positively impact the company's revenue.
The FDA's acceptance of Day One's NDA for Tovorafenib triggers a $5 million milestone payment to XOMA. This additional revenue could positively impact XOMA's financial performance in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100